162. 類天疱瘡(後天性表皮水疱症を含む。) Pemphigoid Clinical trials / Disease details


臨床試験数 : 90 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05061771
(ClinicalTrials.gov)
May 6, 202215/9/2021Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)Bullous PemphigoidDrug: nomacopan (rVA576);Other: PlaceboAKARI TherapeuticsNULLWithdrawn18 Years99 YearsAll0Phase 3United States;Germany;Netherlands;Poland
2EUCTR2020-005987-67-NL
(EUCTR)
22/04/202224/11/2021A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tabletsA randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) moderate to severe bullous pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: nomacopan
Product Code: rVA576
INN or Proposed INN: NOMACOPAN
Other descriptive name: rVA576
Akari Therapeutics PlcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 3United States;Germany;Netherlands
3EUCTR2020-005987-67-DE
(EUCTR)
22/12/202116/07/2021A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tabletsA randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) moderate to severe bullous pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: nomacopan
Product Code: rVA576
INN or Proposed INN: NOMACOPAN
Other descriptive name: rVA576
Akari Therapeutics PlcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 3United States;Germany
4NCT04035733
(ClinicalTrials.gov)
September 25, 201812/4/2019rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsA Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsBullous Pemphigoid (BP)Drug: rVA576AKARI TherapeuticsNULLCompleted18 YearsN/AAll9Phase 2Germany;Netherlands
5EUCTR2017-002836-18-DE
(EUCTR)
23/07/201814/02/2018A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters)A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects Mild to Moderate Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: rVA576
INN or Proposed INN: rVA576
Akari Therapeutics Plc.NULLNot RecruitingFemale: yes
Male: yes
9Phase 2Netherlands;Germany
6EUCTR2017-002836-18-NL
(EUCTR)
07/05/201824/01/2018A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters)A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects Mild to Moderate Bullous Pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: rVA576
INN or Proposed INN: rVA576
Akari Therapeutics Plc.NULLNot RecruitingFemale: yes
Male: yes
9Phase 2Germany;Netherlands